Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Hydralazine has been used in the treatment of hypertension and heart failure for a long time. It has been associated with the development of Vasculitis and Drug induced lupus. This is a male patient in his sixties who was admitted at the hospital and prescribed hydralazine. He developed Hydralazine-induced lupus with Pancytopenia and renal failure. This case report has been written to raise awareness about the hydralazine side effects.

Case Presentation

This case report describes a 68-year-old male, transferred to our hospital for rehabilitation. He was tracheostomized. He is hypertensive with a history of CVA. BP was elevated during the admission. He has no family history of immunological diseases or any allergies. 6 months after hydralazine, the patient started to have a purpuric rash over the lower limbs and an elevated renal profile. Only Direct Coomb’s test was positive. He had hematuria and pancytopenia also. He was started on steroids and he became edematous. On March 2021, the hydralazine was stopped and the patient's blood tests improved, the rash disappeared and hematuria stopped. Unfortunately, he got fungemia and septicemia with pneumonia. He became hypotensive and anuric. The patient kept deteriorating and passed away.

Discussion

Hydralazine is not a first line choice for the treatment of hypertension. Common side effects include tachycardia and headache. It can also cause drug-induced lupus.

Conclusion

Hydralazine has been used in the treatment of hypertension and heart failure for a long time. It has been associated with the development of Vasculitis and Drug induced lupus.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882229825230928073826
2024-01-01
2025-04-24

  • From This Site

    /content/journals/nemj/10.2174/0102506882229825230928073826
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. WilliamJ. case report, hydralazine induced ANCA associated vasculitis.Rheumatol.2021
     [Google Scholar]
  2. ZuckermanR. PatelM. CostanzoE.J. DounisH. RanyA.L. Hydralazine associated adverse event, a report of 2 cases of hydralazine induced ANCA vasculitis, Brazilian.J. Nephrol.201840219397
     [Google Scholar]
  3. MorrowJ.D. SchroederH.A. PerryH.M. Studies on the control of hypertension by hyphex. II. Toxic reactions and side effects.Circulation19538682983910.1161/01.CIR.8.6.82913106903
     [Google Scholar]
  4. ChangC GreshwinME Drug-induced lupus erythematosus: Incidence, management and prevention.Drug Saf201134535774
     [Google Scholar]
  5. FinksSW FinksAL Hydralazine-induced lupus: Maintaining vigilance with increased use in patients with heart failure.South Med J20069911822
     [Google Scholar]
  6. Archives, hydralazine hydrochloride, the American Society of health systems pharmacist2016
     [Google Scholar]
  7. StuartM.C. KouimtizM. HillS.R. WHO model formulary 2008.World Health Organization2009280
     [Google Scholar]
  8. FerdinandKC ElkayamU ManciniD OfiliE PinaI AnandI Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial.Am J Cardiol201411411519
     [Google Scholar]
  9. Camille GeorgesW The Practice of Medicinal Chemistry.Academic press2011
     [Google Scholar]
  10. Birkhauser.Prog. Drug Res.2013206
     [Google Scholar]
  11. World Health Organization World Health Organization model list of essential medicine, 21ST list 2019 Geneva.2019
     [Google Scholar]
  12. Top 300 of 2019.ClinCsal2021
     [Google Scholar]
  13. KandlerMR MahGT TejaniAM StablerSN SalzwedelDM hydralazine for essential hypertension.Cochrane Database Sys. Rev.201111CD004934
     [Google Scholar]
  14. ChampeM.H. Lippincott's Illustrated Reviews Pharmacology.2nd ed.PhiladelphiaLippincott Williams& Wilkins2000
     [Google Scholar]
  15. GurneyA.M. AllamM. Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine.Br. J. Pharmacol.1995114123824410.1111/j.1476‑5381.1995.tb14931.x7712024
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882229825230928073826
Loading
Hydralazine Induced Vasculitis: A Case Report
NEW Emirates Medical J 5, e02506882229825 (2024); https://doi.org/10.2174/0102506882229825230928073826
/content/journals/nemj/10.2174/0102506882229825230928073826
/content/journals/nemj/10.2174/0102506882229825230928073826
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): AKI; Hematuria; Hydralazine; Hypertension; Thrombocytopenia; Vasculitis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test